FPRX - Five Prime Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.53
-0.40 (-3.66%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close10.93
Open10.92
Bid0.00 x 800
Ask0.00 x 900
Day's Range10.49 - 11.14
52 Week Range7.84 - 22.75
Volume162,796
Avg. Volume396,750
Market Cap373.454M
Beta (3Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-4.05
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.57
Trade prices are not sourced from all markets
  • Markit6 days ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    # Five Prime Therapeutics Inc ### NASDAQ/NGS:FPRX View full report here! ## Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining ## Bearish sentiment Short interest | Positive Short interest is low for FPRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 16. ## Money flow ETF/Index ownership | Negative ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding FPRX totaled $224 million. Additionally, the rate of outflows appears to be accelerating. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire6 days ago

    Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that a poster entitled “Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Cancer” was presented today at the ASCO Gastrointestinal Cancer Symposium in San Francisco. The poster (Board J1, Abstract #91) can be found online at Five Prime Therapeutics Scientific Publications. “Gastric cancer with FGFR2b overexpression or FGFR2 gene amplification is associated with a poor prognosis for patients with advanced disease,” said Helen Collins, M.D., senior vice president and chief medical officer of Five Prime.

  • GlobeNewswire8 days ago

    Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
    American City Business Journals8 days ago

    Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line

    The 17-year-old biotech company, a big player in antibody drug research and development, will focus its cash on a maturing pipeline of experimental drugs while letting go of some longtime employees.

  • Business Wire8 days ago

    Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today a corporate restructuring to focus resources on its development pipeline, comprising five clinical-stage cancer programs in various solid tumor types and addressing multiple cell types in the tumor microenvironment. “While we are on track for multiple data read-outs and potential phase advances from our pipeline in 2019, the Executive Team and Board felt it was necessary to sharpen our focus on our current clinical programs and the advancement of our later-stage research initiatives,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.

  • Business Wire9 days ago

    Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium

    – Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric and Gastric Esophageal Junction Cancer –

  • Benzinga10 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    M&A momentum is building in the pharma space, with more deals announced last week, including Eli Lilly And Co (NYSE: LLY )'s $8-billion move to acquire Loxo Oncology Inc (NASDAQ: LOXO ). The following ...

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    # Five Prime Therapeutics Inc ### NASDAQ/NGS:FPRX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining ## Bearish sentiment Short interest | Positive Short interest is low for FPRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on December 18. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding FPRX are favorable, with net inflows of $3.81 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Markitlast month

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    # Five Prime Therapeutics Inc ### NASDAQ/NGS:FPRX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is low for FPRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on December 18. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding FPRX are favorable, with net inflows of $1.55 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wirelast month

    Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 37th Annual J.P.

  • See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    Five Prime Therapeutics Inc NASDAQ/NGS:FPRX

  • Business Wire2 months ago

    Five Prime Therapeutics Announces Changes to its Board of Directors

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today changes to its Board of Directors. Mr. Mark McDade, who has served as a member of Five Prime’s Board of Directors since July 2006 and Lead Independent Director since March 2016, will retire from the Board effective November 30, 2018.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool2 months ago

    3 Top Biotech Stocks to Buy Right Now

    Ignoring these promising biotech stocks could be a mistake.

  • See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    Short interest is moderate for FPRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on November 9.

  • Business Wire2 months ago

    Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference, November 28, 2018 at 11:10 am ET.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FPRX earnings conference call or presentation 6-Nov-18 9:30pm GMT

    Q3 2018 Five Prime Therapeutics Inc Earnings Call

  • See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    Five Prime Therapeutics Inc NASDAQ/NGS:FPRX

  • Business Wire2 months ago

    Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein

    Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced it initiated patient dosing in a Phase 1 clinical trial of FPT155, a first-in-class CD80 fusion protein. “We are pleased to initiate patient dosing for FPT155, our first-in-class CD80-Fc fusion protein, which is engineered to activate T cells through multiple pathways,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “In vivo, FPT155 demonstrates strong single-agent activity in multiple preclinical models, including some that are generally resistant to immune-modulating therapy.

  • Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more
    American City Business Journals2 months ago

    Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more

    Our weekly guide to what's happening in the biotech, medical devices, diagnostics and hospital space.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current.

  • See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    Short interest is low for FPRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on October 23.

  • Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates

    Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -17.09% and -22.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Five Prime Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.37. The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed ...

  • Business Wire3 months ago

    Five Prime Therapeutics Announces Third Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif.-- -- Initiated Phase 3 FIGHT global registrational trial of bemarituzumab in gastric and gastroesophageal junction cancer Initiated FPA150 dosing in B7-H4 positive patients in Phase 1 exploratory cohort Opened enrollment for the FPT155 Phase 1 clinical trial in Australia Announced industry veteran David V. Smith will join as Executive Vice President and Chief Financial Officer ...

  • Business Wire3 months ago

    Five Prime Therapeutics Announces David V. Smith Will Join as Chief Financial Officer

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that industry veteran David V. Smith will join the company as Executive Vice President and Chief Financial Officer (CFO), effective November 26, 2018. As CFO, Mr. Smith will report directly to Chief Executive Officer Aron Knickerbocker and be a member of the Executive Team. “We are delighted to welcome David to Five Prime.